In this issue:
Dupilumab for atopic dermatitis: the RELIEVE-AD study
Dupilumab in atopic dermatitis:4 phase III trials
Drug survival of biologics for hidradenitis suppurativa
Ustekinumab for hidradenitis suppurativa
Risankizumab in moderate-to-severe psoriasis
Secukinumab for psoriasis in Asia-Pacific and Middle East regions
Clinical predictors of omalizumab response in chronic spontaneous urticaria
Late-onset adverse events of anti-PD-1 therapy for melanoma
Vitiligo associated with anti-PD-1 therapy
Please login below to download this issue (PDF)